VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Down 96.2% in April

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totaling 269,068 shares, a decrease of 96.2% from the April 15th total of 7,087,765 shares. Based on an average daily volume of 193,588 shares, the short-interest ratio is presently 1.4 days. Currently, 3.6% of the shares of the company are sold short.

Hedge Funds Weigh In On VolitionRX

A number of large investors have recently added to or reduced their stakes in VNRX. Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRX during the 2nd quarter valued at about $52,000. Virtu Financial LLC bought a new position in shares of VolitionRX in the third quarter worth approximately $28,000. Citadel Advisors LLC grew its holdings in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Lagoda Investment Management L.P. increased its stake in shares of VolitionRX by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after buying an additional 782,000 shares during the period. Finally, Armistice Capital LLC raised its holdings in VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRX Stock Performance

VolitionRX stock traded up $0.26 during mid-day trading on Tuesday, hitting $2.31. 168,773 shares of the company traded hands, compared to its average volume of 450,876. VolitionRX has a one year low of $2.01 and a one year high of $18.80. The stock has a market cap of $18.65 million, a price-to-earnings ratio of -0.52 and a beta of 1.03. The stock has a fifty day moving average price of $3.46 and a 200-day moving average price of $5.11.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on VNRX shares. Citigroup cut VolitionRX to a “hold” rating in a research note on Monday, April 20th. HC Wainwright reduced their target price on shares of VolitionRX from $30.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Finally, D. Boral Capital reissued a “hold” rating on shares of VolitionRX in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.67.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.